大消费概念持续活跃 丽人丽妆3连板 智通财经5月19日电，午后大消费概念持续活跃，医美、宠物经济方向领涨，丽人丽妆走出3连板，拉芳 家化、源飞宠物涨停，天元宠物、锦波生物、百龙创园、路斯股份股价创出历史新高。消息面上，据粤 开证券统计，国内消费医疗对应万亿级市场规模。医美领域市场规模预计2025年达到3529亿元。 ...

Group 1 - The Ministry of Commerce has issued the third batch of best practice cases for the national service industry expansion pilot, focusing on replicable and promotable experiences for service industry development [1] - The best practices include 11 innovative measures across three areas: industrial ecosystem construction, international cooperation, and regional collaboration [1] - The measures reflect collaborative openness and integrated innovation in key industries such as culture, technology, and healthcare [1] Group 2 - The State Administration for Market Regulation is soliciting public opinions on the revised draft regulations to curb the abuse of administrative power that restricts competition [2] - The National Bureau of Statistics reported that the average annual salary for urban non-private and private sector employees in 2024 will be CNY 124,110 and CNY 69,476, respectively [2] Group 3 - The Ministry of Finance and the Financial Regulatory Bureau have announced a push for the digitalization of bank confirmations to enhance efficiency and security [3] - The notification emphasizes the importance of increasing the number of entities accessing the bank confirmation platform [3] Group 4 - The Ministry of Commerce and the National Development and Reform Commission have revised the "Catering Industry Promotion and Management Measures," adding provisions to encourage international cooperation and digital development [4] - The revised measures include 25 articles aimed at promoting high-quality development in the catering industry [4] Group 5 - The State-owned Assets Supervision and Administration Commission announced personnel changes in 10 central enterprises, including leadership appointments and removals [5][6] Group 6 - The China Securities Regulatory Commission encourages private equity funds to participate in mergers and acquisitions of listed companies, with adjustments to lock-up periods for investments [7] - The Shenzhen Stock Exchange is monitoring stocks with abnormal price fluctuations, including "ST Yushun" and "ST Jiajia" [8] Group 7 - The Shenzhen Stock Exchange will host the 2025 Global Investor Conference to showcase the investment value of Chinese assets and the A-share market [9] Group 8 - The Ministry of Industry and Information Technology is accelerating the development of 5G-A and 6G technologies to support modern industrial systems [13] - The National Data Bureau aims for the core value added of the digital economy to exceed 10% of GDP by the end of 2025 [14] Group 9 - The Ministry of Industry and Information Technology reported that China has built the world's largest and most advanced information and communication network, with 5G applications covering 86 of 97 national economic categories [15] Group 10 - Binhai Energy plans to acquire 100% equity of Cangzhou Xuyang Chemical Co., Ltd., with the stock expected to resume trading on May 19, 2025 [17] - The automotive industry is set to benefit from a significant release of funds due to a recent reserve requirement ratio cut, potentially exceeding CNY 1 trillion [18] Group 11 - Xiaomi's President revealed that products using the self-developed "Xuanjie" chip will extend beyond smartphones [21] - Huamin Co. and Tiantai Robotics signed a strategic cooperation agreement to advance the robotics industry [21] Group 12 - Xiangzi High-Tech announced the sale of an 80% stake in Heilongjiang Yunfeng Automobile Co., Ltd. for CNY 24.6 million, aiming to restructure its fuel vehicle business [22] - ST Kexin has successfully removed its delisting risk warning and will change its stock name to Kexin Development [23] Group 13 - *ST Aonong has received approval to remove its delisting risk warning, with its stock name changing to Aonong Biological [24][25] - Jianghan New Materials plans to repurchase shares worth CNY 200 million to CNY 400 million [26] Group 14 - Siyuan Electric intends to repurchase shares worth CNY 300 million to CNY 500 million [27] - Liren Lizhuang reported that products containing "Mikang Sulfur" have a minimal impact on overall business performance [28] Group 15 - Jinhe Biological's controlling shareholder plans to reduce its stake by up to 3% [29] - Guanghui Energy announced the transfer of 15.03% of its shares to two insurance companies [30] Group 16 - Tailing Microelectronics reported a reduction in the National Big Fund's shareholding to 6.95% [31] - AVIC High-Tech plans to invest CNY 918 million to enhance its capabilities in aviation composite materials [32]

Core Viewpoint - The recent public endorsement of ergotinine by Liu Gexin, chairman of Kelong Pharmaceutical, has sparked significant interest in the A-share market, particularly in stocks related to ergotinine, leading to substantial price increases for several companies [2][8]. Group 1: Market Reaction - Following Liu Gexin's public display of fitness and claims of long-term ergotinine use, stocks such as Liren Lizhuang, Chuaning Biological, and Tuoxin Pharmaceutical experienced notable price surges, with Liren Lizhuang hitting the daily limit for two consecutive trading days [2][8]. - As of May 16, Liren Lizhuang's stock price reached 9.43 yuan per share, with a total market capitalization of 3.776 billion yuan [7]. Group 2: Company Responses - Liren Lizhuang confirmed that it has no undisclosed significant information and noted that its product containing ergotinine, "Qianjin Jiguang Drink," contributes minimally to overall revenue [4][7]. - Other companies, such as Wanbang Pharmaceutical and Fushijia, have responded to investor inquiries regarding their involvement with ergotinine, indicating ongoing research and exploration of its potential benefits [8]. Group 3: Ergotinine Overview - Ergotinine, discovered in 1909, is recognized as a potent antioxidant with various physiological functions, including free radical scavenging and cellular protection [7]. - The compound has applications across multiple industries, including cosmetics and health foods, with increasing recognition in the market, although awareness remains low domestically [7][8].

Core Viewpoint - Shanghai Liren Lizhuang Cosmetics Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of over 20% on May 15 and 16, 2025, which is classified as an abnormal trading situation according to Shanghai Stock Exchange regulations [2][3]. Group 1: Stock Trading Situation - The company's stock price showed a cumulative increase of over 20% on May 15 and 16, 2025, indicating abnormal trading activity [2][3]. - The actual fluctuation of the stock price, after excluding the overall market and sector factors, was relatively large [10]. Group 2: Company Operations and Major Events - The company confirmed that its daily operations are normal, and there have been no significant changes in the market environment or industry policies [4]. - There are no undisclosed major events affecting the stock price, including significant asset restructuring, share issuance, or major business collaborations [5][8]. Group 3: Product and Revenue Impact - The product containing "ergothioneine," such as the self-owned brand Meiyitang's oral product "Qianjin Jiguang Drink," is primarily positioned for skin conditioning and beauty enhancement, with ergothioneine being a minor additive [6]. - The revenue from products containing "ergothioneine" constitutes a very low percentage of the company's overall revenue, having minimal impact on daily operations and overall performance [7][10].

Group 1 - The concept of ergot sulfur has gained popularity, leading to significant stock price movements among related companies, with some experiencing a daily limit increase [1][3] - Kelong Pharmaceutical has been actively promoting ergot sulfur, with its chairman showcasing the product's potential in an advertisement, which has contributed to the surge in related stocks [1][2] - Several companies have responded to investor inquiries regarding their involvement with ergot sulfur, indicating that the revenue from products containing this ingredient is currently low and has minimal impact on overall performance [3] Group 2 - Kelong Pharmaceutical has been focusing on the health industry for seven years, emphasizing the commercialization of ergot sulfur as a key growth factor [2] - Other companies, such as Haizheng Pharmaceutical and Wanbang Pharmaceutical, are also exploring the potential applications of ergot sulfur, with ongoing research and development efforts [3]

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen markets announced significant developments, providing insights for investors [2] Investment Activities - Ningde Times plans to invest up to $225 million in the Lochpine Green Fund I, LP, focusing on carbon neutrality, with a target size of $1.5 billion [3] - Baiyun Airport intends to invest 4.5 million yuan to establish a duty-free company with partners, with a total registered capital of 45 million yuan [4] - Guizhou Moutai has repurchased a total of 2.6421 million shares, amounting to 4.05 billion yuan, representing 0.2103% of its total share capital [5] - Zhonghang Gaoke's subsidiary plans to invest 918 million yuan in enhancing capabilities for civil aviation composite materials [12] Shareholding Changes - Huaxi Group will transfer 16.01% of its shares in Chengxing Co. to Jiangyin Lianying for 511 million yuan, with no change in controlling shareholder [6] - Tunnel Co.'s controlling shareholder plans to increase its stake by investing between 250 million to 500 million yuan [13] Stock Adjustments - *ST Aonong will remove its delisting risk warning, changing its name to Aonong Biological, with a price fluctuation limit adjustment from 5% to 10% [7] - *ST Kexin will also remove its delisting risk warning, changing its name to Kexin Development, with similar price fluctuation adjustments [9] Market Performance - Ningbo Shipping reported normal operations and no undisclosed significant information, with its rolling P/E ratio significantly higher than the industry average [8] - Liren Lizhuang stated that products containing "ergothioneine" contribute minimally to overall sales, indicating limited impact on business performance [10] Share Buyback Plans - Jianghan New Materials plans to repurchase shares worth 200 million to 400 million yuan, with a maximum price of 30 yuan per share [14]

Group 1 - The China Securities Regulatory Commission (CSRC) encourages private equity funds to participate in mergers and acquisitions of listed companies, establishing a simplified review process for the first time [1] - The CSRC has adjusted regulatory requirements for issuing shares to purchase assets and introduced a phased payment mechanism for the first time [1] - The CSRC has introduced a "reverse linkage" arrangement for private equity funds for the first time [1] Group 2 - Multiple public fund industry insiders stated that recent analyses regarding public fund assessment benchmarks leading to market adjustments are inaccurate and lack basic knowledge and evidence [2] Group 3 - The Hong Kong Hang Seng Index will include Midea Group and ZTO Express, while BYD will join the Hang Seng Tech Index, removing Reading Group [3] Group 4 - E Fund announced that renowned fund manager Zhang Kun will no longer serve as deputy general manager due to work adjustments and will focus on investment management in the future [4] Group 5 - Jinlitai's board disagreed with shareholders' proposal to convene an extraordinary general meeting [5] - 20CM's two consecutive trading limits for Toxin Pharmaceutical: Ivos will reduce its holdings by 1.3128 million shares from March 14 to May 15, 2025 [5] - Tailing Microelectronics: The National Fund's shareholding ratio has decreased to 6.95% [5] - Two consecutive trading limits for Liren Liyang: The revenue proportion of ergotamine products is very low [5] - Tunnel Holdings: The controlling shareholder plans to increase its stake in the company by 250 million to 500 million yuan [5] - CATL announced the H-share offering price set at HKD 263.00 per share [5]

Core Viewpoint - Shanghai Liren Lizhuang Cosmetics Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days on May 15 and May 16, 2025, which is classified as an abnormal trading situation according to Shanghai Stock Exchange regulations [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price showed a cumulative closing price increase of over 20% on May 15 and May 16, 2025, indicating abnormal trading activity [1][2]. - The company conducted a self-examination and confirmed that there are no undisclosed significant information affecting the stock price [2]. Group 2: Business Operations - The company's daily operations are reported to be normal, with no significant changes in market environment or industry policies [2]. - The company verified with its controlling shareholder that there are no undisclosed major events affecting stock price fluctuations, including major asset restructuring or significant business cooperation [2]. Group 3: Product Information - The product containing "ergothioneine," specifically the self-owned brand Meiyitang's oral product "Qianjin Jiguang Drink," has a low sales revenue contribution to the overall business, thus having minimal impact on daily operations and overall performance [2][3]. - The "ergothioneine" is a minor auxiliary additive in the product, primarily aimed at skin conditioning and beauty enhancement [2]. Group 4: Board Statements - The board of directors confirmed that there are no undisclosed matters that should be disclosed according to the Shanghai Stock Exchange's listing rules, and previous disclosures do not require correction or supplementation [4]. - The company emphasizes that all information should be based on disclosures made in designated media outlets [4].

上海丽人丽妆化妆品股份有限公司（以下简称"公司"或 "丽人丽妆"）股票价格于 2025 年 5 月 15 日、5 月 16 日连续 两个交易日内日收盘价格涨幅偏离值累计超过 20%。根据上海证 券交易所的相关规定，属于股票交易异常波动情形。 经公司董事会自查及发函问询控股股东、实际控制人，截 至本公告披露日，公司不存在应披露而未披露的重大信息。 相关媒体报道、市场传闻说明及风险提示：就目前市场上 较为关注的"麦角硫因"成分，公司销售的含有"麦角硫因"成 分的产品销售收入整体占比很低，对于公司整体日常经营及整体 业绩影响很小。公司敬请广大投资者注意二级市场交易风险，理 性决策，审慎投资。 证券代码：605136 证券简称：丽人丽妆 公告编号：2025-029 上海丽人丽妆化妆品股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： 一、股票交易（异常）波动的具体情况 公司股票价格于 2025 年 5 月 15 日、5 月 16 日连续两个交 易日内日收盘价格涨幅偏离值累计超过 20% ...

Group 1 - The company, Liren Lizhuang (605136.SH), announced that its stock price has experienced an abnormal fluctuation, with a cumulative increase of over 20% in closing prices over two consecutive trading days [1] - After verification, the company confirmed that there is no undisclosed significant information that should be disclosed [1] - The company's self-owned brand, Meiyitang, includes a product called "Qianjin Jiguang Drink," which contains the ingredient Ergothioneine; however, this product contributes a very low percentage to the company's overall revenue, thus having minimal impact on daily operations and overall performance [1]